Kaken Pharmaceutical (4521) Q1 2025 earnings summary

Executive summary

• Net sales for the first quarter of fiscal 2024 were ¥18,254 million, up 0.6% year-over-year.

• Operating profit declined 16.5% year-over-year to ¥2,750 million.

• Ordinary profit decreased 13.7% year-over-year to ¥3,011 million.

• Profit attributable to owners of the parent dropped 30.1% year-over-year to ¥1,754 million.

• Comprehensive income fell 57.8% year-over-year to ¥1,607 million.

Financial highlights

• Gross profit for the quarter was ¥10,052 million, nearly flat year-over-year.

• Selling, general and administrative expenses increased to ¥7,301 million from ¥6,762 million year-over-year.

• Research and development expenses rose to ¥2,998 million from ¥2,600 million year-over-year.

• Basic earnings per share for the quarter was ¥46.32, down from ¥66.99 in the prior year.

Outlook and guidance

• Full-year fiscal 2025 net sales forecast is ¥88,500 million, up 22.8% year-over-year.

• Operating profit is projected at ¥20,800 million, up 118.6% year-over-year.

• Profit attributable to owners of the parent is forecast at ¥14,200 million, up 76.9% year-over-year.

• Basic earnings per share for the year is forecast at ¥374.97.

• Dividend forecast for fiscal 2025 is ¥190.00 per share, including a ¥40.00 bonus dividend in the second quarter.